Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Pauline WilsPhilippe SeksikCarmen StefanescuStephane NanceyMatthieu AllezGuillaume Pineton de ChambrunRomain AltweggCyrielle GillettaLucine VuittonStéphanie ViennotMélanie SerreroMathurin FumeryGuillaume SavoyeMichael CollinsFelix GoutorbeHedia BrixiGuillaume BouguenNoémie TavernierMedina BoualitAurélien AmiotVered AbitbolDavid LaharieBenjamin Parientenull nullPublished in: Alimentary pharmacology & therapeutics (2020)
We report 73 pregnancies in patients receiving vedolizumab or ustekinumab without a negative signal on maternal or neonatal outcomes. Further prospective studies are needed on the outcomes of pregnancies with new biologic drugs.
Keyphrases
- patient reported outcomes
- ulcerative colitis
- preterm birth
- pregnancy outcomes
- rheumatoid arthritis
- end stage renal disease
- pregnant women
- gestational age
- clinical trial
- patients with inflammatory bowel disease
- chronic kidney disease
- birth weight
- randomized controlled trial
- ejection fraction
- newly diagnosed
- study protocol
- prognostic factors
- peritoneal dialysis